| Literature DB >> 26317209 |
M Reza Sailani1, Federico A Santoni2, Audrey Letourneau1, Christelle Borel2, Periklis Makrythanasis2, Youssef Hibaoui3, Konstantin Popadin2, Ximena Bonilla2, Michel Guipponi2, Corinne Gehrig2, Anne Vannier2, Frederique Carre-Pigeon4, Anis Feki3, Dean Nizetic5, Stylianos E Antonarakis6.
Abstract
DNA methylation is essential in mammalian development. We have hypothesized that methylation differences induced by trisomy 21 (T21) contribute to the phenotypic characteristics and heterogeneity in Down syndrome (DS). In order to determine the methylation differences in T21 without interference of the interindividual genomic variation, we have used fetal skin fibroblasts from monozygotic (MZ) twins discordant for T21. We also used skin fibroblasts from MZ twins concordant for T21, normal MZ twins without T21, and unrelated normal and T21 individuals. Reduced Representation Bisulfite Sequencing (RRBS) revealed 35 differentially methylated promoter regions (DMRs) (Absolute methylation differences = 25%, FDR < 0.001) in MZ twins discordant for T21 that have also been observed in comparison between unrelated normal and T21 individuals. The identified DMRs are enriched for genes involved in embryonic organ morphogenesis (FDR = 1.60 e -03) and include genes of the HOXB and HOXD clusters. These DMRs are maintained in iPS cells generated from this twin pair and are correlated with the gene expression changes. We have also observed an increase in DNA methylation level in the T21 methylome compared to the normal euploid methylome. This observation is concordant with the up regulation of DNA methyltransferase enzymes (DNMT3B and DNMT3L) and down regulation of DNA demethylation enzymes (TET2 and TET3) observed in the iPSC of the T21 versus normal twin. Altogether, the results of this study highlight the epigenetic effects of the extra chromosome 21 in T21 on loci outside of this chromosome that are relevant to DS associated phenotypes.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26317209 PMCID: PMC4552626 DOI: 10.1371/journal.pone.0135555
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Description of samples used for DNA methylation analyses.
| Sample set | Sample ID | Gender | Description | Age | Passage |
|---|---|---|---|---|---|
| MZ twins discordant for T21 (Replicate 1) | Sample 1 | Female | Normal primary fetal skin fibroblasts | 13 WG | P13 |
| MZ twins discordant for T21 (Replicate 1) | Sample 2 | Female | T21 primary fetal skin fibroblasts | 13 WG | P13 |
| MZ twins discordant for T21 (Replicate 2) | Sample 3 | Female | Normal primary fetal skin fibroblasts | 13 WG | P13 |
| MZ twins discordant for T21 (Replicate 2) | Sample 4 | Female | T21 primary fetal skin fibroblasts | 13 WG | P13 |
| T21 MZ twins discordant for VSD | Sample 5 | Male | T21 with VSD primary skin fibroblasts | 4 years | P5 |
| T21 MZ twins discordant for VSD | Sample 6 | Male | T21 without VSD primary skin fibroblasts | 4 years | P5 |
| T21 MZ twins discordant for AVSD | Sample 7 | Male | T21 with AVSD amniocytes | 17 WG | NA |
| T21 MZ twins discordant for AVSD | Sample 8 | Male | T21 without AVSD amniocytes | 17 WG | NA |
| Normal MZ twins pair 1 | Sample 9 | Female | Normal primary fetal skin fibroblasts | Fetal | P5 |
| Normal MZ twins pair 1 | Sample 10 | Male | Normal primary fetal skin fibroblasts | Fetal | P5 |
| Normal MZ twins pair 2 | Sample 11 | Female | Normal primary skin fibroblasts | 53 years | P8 |
| Normal MZ twins pair 2 | Sample 12 | Female | Normal primary skin fibroblasts | 53 years | P9 |
| Unrelated normal and T21 | Sample 13 | Female | T21 primary skin fibroblasts | 3 days | P14 |
| Unrelated normal and T21 | Sample 14 | Female | Normal primary skin fibroblasts | 2 days | P14 |
| MZ twins discordant for T21 iPS cells | Sample 15 | Female | Normal iPS cells | 13 WG | P10 |
| MZ twins discordant for T21 iPS cells | Sample 16 | Female | T21 iPS cells | 13 WG | P10 |
| MZ twins discordant for T21 iPS cells | Sample 17 | Female | T21 iPS cells | 13 WG | P10 |
*WG, Weeks of Gestation.
NA, Not Applicable
Fig 1CpGs Coverage of MZ-twins discordant for T21.
A) Distributions of covered CpGs (≥20X read coverage) by RRBS in promoters, exons, introns, and intergenic regions are shown in the pie chart. The blue bar in the histogram panel shows how many percentages of the genomic features are covered by RRBS. B) Distributions of covered CpGs (≥20X read coverage) by RRBS in CpG islands.
Fig 2The overall DNA methylation level at single CpG resolution, and over genomic features.
The probability density distribution and the box-plot of DNA methylation shows differences between the T21 twin and the normal twin at the level of A) single CpG sites, B) promoters, C) CpG islands, D) Exons, E) Introns, F) LADs, and G) iLADs. The red line in the probability plot shows the probability distribution of T21 twin methylome subtracted from the normal twin methylome (T21—N). While, the blue line shows the probability distribution of the normal twin methylome subtracted from T21 twin methylome (N—T21). DNA hyper-methylation in T21 twin (T21 > Normal) is observed at the level of CpGs, and all the genomic features, but the effect is more pronounced in promoters and CpG islands.
Fig 3DNA methylation profile over a “Gene Model”.
DNA methylation fold change in A) Monozygotic twins discordant for T21, B) Unrelated T21 and normal cases, C) Normal MZ twins, D) T21 MZ twins. TSS and TTS represent transcription start site and transcription termination sites, respectively. The plot shows an increase in the level of DNA methylation around TSS in T21 twin compared to the normal twin.
Fig 4Strategy used to define DMRs of gene promoters induced by the extra copy of chr21 in MZ twins discordant for T21.
DMRs are identified in each pair of twins, as well as unrelated normal and T21 cases. DMRs that are common among MZ twins discordant for T21, T21 MZ twins, and normal MZ twins have been excluded from the final candidate list. Subsequently, from this reduced list of DMRs, those that have been observed in unrelated T21 and normal individuals were selected as T21 induced candidate DMRs for further analyses. Each horizontal blue bar represents one pair of sample. The red vertical bars show DMRs. The numbers on the right side of each blue bar shows the number of identified DMRs in each pair of sample.
DMRs in MZ twin discordant for T21.
| Chr. | Start | End | Meth (T21-N) | Gene name | Gene description |
|---|---|---|---|---|---|
| chr1 | 24016268 | 24019268 | 68.33 |
| Ribosomal protein L11 |
| chr1 | 115123265 | 115126265 | 33.29 |
| Breast carcinoma amplified sequence 2 |
| chr1 | 115123265 | 115126265 | 33.29 |
| DENN/MADD domain containing 2C |
| chr1 | 155909479 | 155912479 | 26.17 |
| Relaxin/insulin-like family peptide receptor 4 |
| chr2 | 26780566 | 26783566 | 26.11 |
| Otoferlin |
| chr2 | 176962529 | 176965529 | 55.30 |
| Homeobox D12 |
| chr2 | 176979491 | 176982491 | 62.16 |
| Homeobox D10 |
| chr2 | 177026804 | 177029804 | 35.19 |
| Homeobox D3 |
| chr3 | 183722125 | 183725125 | -33.80 |
| ATP-binding cassette, sub-family C |
| chr3 | 195941382 | 195944382 | 25.26 |
| Solute carrier family 51 |
| chr5 | 79550898 | 79553898 | 49.96 |
| Serine incorporator 5 |
| chr5 | 140798536 | 140801536 | 25.12 |
| Protocadherin gamma subfamily A |
| chr5 | 179498118 | 179501118 | -26.77 |
| Ring finger protein 130 |
| chr7 | 129140319 | 129143319 | 43.34 |
| Small lysine-rich protein 1 |
| chr7 | 148934741 | 148937741 | 47.16 |
| Zinc finger protein 212 |
| chr8 | 104381742 | 104384742 | 31.30 |
| Collagen triple helix repeat containing 1 |
| chr9 | 35904188 | 35907188 | -25.15 |
| Histidine rich carboxyl terminus 1 |
| chr9 | 131682561 | 131685561 | -39.51 |
| Phytanoyl-coa dioxygenase domain 1 |
| chr9 | 132403448 | 132406448 | 40.11 |
| Ankyrin repeat and SOCS box containing 6 |
| chr9 | 133882503 | 133885503 | 30.65 |
| Laminin, gamma 3 |
| chr10 | 100027007 | 100030007 | 41.49 |
| Lysyl oxidase-like 4 |
| chr11 | 17564963 | 17567963 | 41.50 |
| Usher syndrome 1C |
| chr15 | 74464086 | 74467086 | 38.36 |
| Immunoglobulin superfamily leucine-rich |
| chr15 | 91471409 | 91474409 | 39.87 |
| HD domain containing 3 |
| chr16 | 68266402 | 68269402 | 33.39 |
| Epithelial splicing regulatory protein 2 |
| chr16 | 73124247 | 73127247 | 31.28 |
| Hepatocellular carcinoma transcript 5 |
| chr16 | 75527926 | 75530926 | 52.13 |
| Carbohydrate |
| chr17 | 8868029 | 8871029 | 25.36 |
| Phosphoinositide-3-kinase |
| chr17 | 46671319 | 46674319 | 45.27 |
| Homeobox B5 |
| chr17 | 46671319 | 46674319 | 45.27 |
| Homeobox B6 |
| chr19 | 4866780 | 4869780 | 44.22 |
| Perilipin 3 |
| chr19 | 36247043 | 36250043 | 27.12 |
| Heat shock protein B6 |
| chr19 | 46848250 | 46851250 | 25.66 |
| Protein phosphatase 5, catalytic subunit |
| chr19 | 55585220 | 55588220 | 30.81 |
| EPS8-like 1 |
| chr20 | 30223690 | 30226690 | -26.72 |
| Cytochrome c oxidase subunit IV isoform 2 |
| chr20 | 45279100 | 45282100 | 25.21 |
| Solute carrier family 13 |
| chr21 | 46338949 | 46341949 | 55.20 |
| Integrin, beta 2 |
*Meth (T21 –N) represents the percent methylation difference between T21 twin and normal twin. The positive sign means T21 twin is more methylated than the Normal twin, and the negative sign means Normal twin is more methylated than T21 twin.
GO terms associated with DMRs identified in MZ twins discordant for T21.
| Biological Process | Gene Name | Gene Description |
|
|
|---|---|---|---|---|
| Embryonic organ morphogenesis |
| Homeobox D3 | 6.52E-06 | 1.60E-03 |
|
| Collagen triple helix repeat containing 1 | |||
|
| Usher syndrome1C | |||
|
| Homeobox B5 | |||
|
| Homeobox B6 | |||
|
| Homeobox D10 | |||
| Embryonic skeletal system morphogenesis |
| Homeobox D3 | 2.79E-05 | 3.40E-03 |
|
| Homeobox B5 | |||
|
| Homeobox B6 | |||
|
| Homeobox D10 | |||
| Embryonic morphogenesis |
| Homeobox D12 | 7.85E-05 | 3.40E-03 |
|
| Homeobox D3 | |||
|
| Homeobox B5 | |||
|
| Homeobox B6 | |||
|
| Homeobox D10 | |||
|
| Collagen triple helix repeat containing 1 | |||
|
| Usher syndrome1C |
P, nominal p-value.
FDR, False Discovery Rate- Benjamini–Hochberg.
DNA methylation differences and gene expression fold changes in fibroblasts and iPSC of MZ twins discordant for T21; the genes listed are from Table 3.
| MZ twins discordant for T21 fibroblast cells | MZ twins discordant for T21 iPS cells | |||
|---|---|---|---|---|
| Gene name | Methylation difference | Gene expression difference Log2 (T21/Normal) | Methylation difference | Gene expression difference Log2 (T21 iPS /Normal iPS) |
|
| 35.2 | -0.80 | 36.4 | -5.7 |
|
| 62.16 | -2.84 | -6.8 | -1.02 |
|
| 45.3 | -0.32 | 59 | -7 |
|
| 45.3 | -1.85 | 59 | -5 |
|
| 31.3 | -0.30 | -53.4 | 0.43 |
|
| 41.5 | 00.0 | -5 | 0.4 |
|
| 60.58 | 3.12 | 77.92 | -0.03 |
|
| -0.86 | -0.56 | ||
* Methylation difference is the percent methylation differences between fibroblast cells of T21 twin and Normal twin (column 2) and between iPS cells of T21 twin and Normal twin (column 4).
Correlation is the Pearson correlation between DNA methylation differences in column 2 and Log2 ratio of gene expression differences in column 3, and between DNA methylation differences in column 4 and Log2 ratio of gene expression differences in column 5.
Histone modification and TFBS enrichment analyses of DMRs associated with T21.
|
| |||
|
|
|
|
|
| H3K27me3 | 9E-05 | 0.01 |
|
| H3K4me1 | 5E-04 | 0.03 |
|
| H2AFZ | 2E-03 | 0.06 |
|
|
| |||
|
|
|
|
|
| CTCF | 2E-04 | 0.1 |
|
| EZH2 | 1E-03 | 0.1 |
|
P, nominal p-value.
FDR, False Discovery Rate- Benjamini–Hochberg.
Fig 5Gene expression fold changes of enzymes involved in DNA methylation.
The log2 ratio of fold change is based on the average RPKM values of four normal twin iPS cell replicates and the average RPKM values of three T21 twin iPS cell replicates.
Common DMRs observed in the two sets of T21 MZ twins discordant for AVSD and VSD.
| Gene | Gene description | AVSD Twins | VSD Twins | Log2FC | Ref. |
|---|---|---|---|---|---|
| Meth. differences | Meth. differences | ||||
|
| Protocadherin gamma subfamily B, 1 | -44.44 | -43.88 | -1.59 | - |
|
| 6-phosphofructo-2-kinase | 29.67 | 92.29 | -1.6 | - |
|
| Transient receptor potential cationchannel | -26.14 | -43.45 | -0.86 | Ref. ( |
|
| WD repeat domain 27 | -29.23 | -27.91 | -1 | - |
|
| YOD1 deubiquitinase | 29.66 | 92.28 | -1.4 | Ref. ( |
|
| Core-binding factor, runt domain | 26.46 | -26.06 | 0.09 | Ref. ( |
|
| Cysteine-serine-rich nuclear protein 2 | 26.21 | 55.58 | -1.5 | - |
|
| DIP2 disco-interacting protein 2 homolog C | -34.88 | -25.81 | -1.32 | - |
|
| EPH receptor A8 | 30.86 | -33.74 | 1 | - |
|
| Lymphocyte antigen 9 | -55.7 | 34.54 | NA | - |
|
| Nuclear factor of activated T-cells | -30.08 | -25.81 | -1 | Ref. ( |
|
| Solute carrier family 9 | -38.78 | 32.26 | -1.8 | Ref. ( |
|
| Troponin T type 3 | -36.11 | -59.85 | 0 | Ref. ( |
Methylation differences show the DNA methylation percent difference between normal twin and twin with cardiac defect. Log2FC shows log2 fold change of RPKM value of gene expression in T21 normal twin over T21 twin with VSD. Gene expression data for T21 twins discordant for AVSD is not available. NA, Not available.
GO terms associated with DMRs identified in T21 MZ twins discordant for CHD.
|
| ||||
|
|
|
|
|
|
| Endocardial cushion morphogenesis |
| Endoglin | 4.08E-05 | 9.00E-03 |
|
| T-box 2 | |||
|
| Recombination signal binding protein | |||
|
| SRY box 9 | |||
| Metanephric nephron tubule formation |
| Paired box 2 | 8.01E-06 | 8.00E-03 |
|
| SRY box 9 | |||
|
| Paired box 8 | |||
|
| ||||
| Pyridine-containing compound metabolic process |
| Pyridoxamine 5'-phosphate oxidase | 4.64E-05 | 3.30E-02 |
|
| Glucokinase | |||
|
| Nudix | |||
|
| Nicotinamide riboside kinase 2 | |||
|
| NAD kinase | |||
|
| Lactate dehydrogenase B | |||
P, nominal p-value.
FDR-BH, False Discovery Rate- Benjamini–Hochberg.
Histone modification and TFBS enrichment analyses of DMRs associated with VSD.
|
| |||
|
|
|
|
|
| H2AFZ | 3.2E-08 | 1.3E-05 |
|
|
| |||
|
| |||
|
| |||
| H3K4me1 | 3.0E-05 | 3.1E-03 |
|
|
| |||
|
| |||
| H3K27ac | 4.1E-05 | 3.4E-03 |
|
|
| |||
|
| |||
|
| |||
|
| |||
|
|
|
|
|
| POLR2A | 7.7E-08 | 3.1E-05 |
|
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
| EP300 | 1.1E-06 | 9.3E-05 |
|
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
| CTCF | 1.3E-06 | 9.4E-05 |
|
|
| |||
|
| |||
|
| |||
|
| |||
P, nominal p-value.
FDR, False Discovery Rate- Benjamini–Hochberg.
Histone modification and TFBS enrichment analyses of DMRs associated with AVSD.
|
| |||
|
|
|
|
|
| H3K4me1 | 1E-05 | 0.006 |
|
|
| |||
| H3K27me3 | 6E-04 | 0.052 |
|
|
| |||
|
| |||
| EP300 | 2E-05 | 0.018 |
|
|
| |||
|
| |||
|
| |||
| E2F6 | 2E-04 | 0.049 |
|
|
| |||
| SMC3 | 1E-04 | 0.049 |
|
|
| |||
| CEBPB | 2E-04 | 0.049 |
|
|
| |||
P, nominal p-value.
FDR, False Discovery Rate- Benjamini–Hochberg.